At the news
? MIXEDIMPACT 5/10 8-K filed May 7, 2026 at 09:24 ET
Harmony Biosciences reported Q1 2026 revenue of $215.4M (+17% YoY), slightly below consensus of $220.8M. GAAP diluted EPS of $0.55 missed consensus of $0.93 by 41%, driven by $32M in upfront license payments. The company reaffirmed FY2026 revenue guidance of $1.0B-$1.04B, citing continued WAKIX growth and pipeline progress.
- Q1 2026 net product revenue $215.4M, +17% YoY ($184.7M)
- GAAP net income $32.5M ($0.55 diluted) vs $45.6M ($0.78) in Q1 2025
- EPS missed consensus ($0.93) by 41% due to $32M in upfront license payments ($0.45 after-tax impact)
- Reiterated FY2026 revenue guidance of $1.0B-$1.04B
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access